Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.

Literature DB >> 25363875

Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.

A Berlin¹, A Dal Pra, R G Bristow.

Abstract

Entities: Disease Species

Mesh：

Year: 2015 PMID： 25363875 PMCID： PMC4277390 DOI： 10.1259/bjr.20140701

Source DB: PubMed Journal: Br J Radiol ISSN： 0007-1285 Impact factor: 3.039

Keyword Cloud
References

× No keyword cloud information.

27 in total

1. Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer.

Authors: C Alberti
Journal: Br J Radiol Date: 2015-01 Impact factor: 3.039

Review 2. Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

Authors: Sarah L Kerns; Harry Ostrer; Barry S Rosenstein
Journal: Cancer Discov Date: 2014-01-17 Impact factor: 39.397

3. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer.

Authors: Michael Milosevic; Padraig Warde; Cynthia Ménard; Peter Chung; Ants Toi; Adrian Ishkanian; Michael McLean; Melania Pintilie; Jenna Sykes; Mary Gospodarowicz; Charles Catton; Richard P Hill; Robert Bristow
Journal: Clin Cancer Res Date: 2012-03-31 Impact factor: 12.531

Review 4. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

Authors: Norman Chan; Robert G Bristow
Journal: Clin Cancer Res Date: 2010-09-07 Impact factor: 12.531

5. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

Authors: Vincent A Potiron; Rym Abderrahmani; Rym Abderrhamani; Eric Giang; Sophie Chiavassa; Emmanuelle Di Tomaso; Sauveur-Michel Maira; François Paris; Stéphane Supiot
Journal: Radiother Oncol Date: 2013-01-12 Impact factor: 6.280

6. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

Authors: Roy Vergis; Catherine M Corbishley; Andrew R Norman; Jaclyn Bartlett; Sameer Jhavar; Michael Borre; Sara Heeboll; Alan Horwich; Robert Huddart; Vincent Khoo; Ros Eeles; Colin Cooper; Matthew Sydes; David Dearnaley; Chris Parker
Journal: Lancet Oncol Date: 2008-03-17 Impact factor: 41.316

Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply.

1. Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer.

Review 2. Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.

3. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer.

Review 4. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair.

5. Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions.

6. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.

7. Hypoxia provokes base excision repair changes and a repair-deficient, mutator phenotype in colorectal cancer cells.

8. Hypoxia promotes migration and induces CXCR4 expression via HIF-1α activation in human osteosarcoma.

9. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway.

10. Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation.